Javier R. Rodríguez-Carrio (Spain)
Facultad de Medicina y CC de la Salud, Universidad de Oviedo
Area of Immunology, 4 floor, office D01
Javier is an assistant professor of immunology at the University of Oviedo and researcher at the ISPA (Spain). After completing a research stay at the Academic Medical Centre (Amsterdam, The Netherlands) on the role of lymph node activation in early rheumatoid arthritis, he obtained his PhD from the University of Oviedo in 2015. During his postdoctoral years, he become interested in the interplay between microbiota and lipid metabolism and endothelial damage in chronic kidney disease. His current research interests are the endothelial damage and vascular repair during the very early stage of rheumatic diseases, with special focus on translational biomarkers for cardiovascular risk assessment, as well as high-throughput lipoprotein approaches and lipidomics in chronic conditions. Javier has been a board member of the EMEUNET working group, and he serves in the EULAR Journal Club team as well as Social Media Editor in Annals of the Rheumatic Diseases and RMD Open. He currently serves as social media ambassador for the EAS.

Presenter of 1 Presentation

 Conference Calendar

O007 - HUMORAL RESPONSES AGAINST HDL ARE LINKED TO LIPOPROTEIN TRAITS, ATHEROSCLEROSIS, INFLAMMATION AND PATHOGENIC PATHWAYS DURING EARLY ARTHRITIS STAGES (ID 49)

Session Name
0160 - New insight in HDL and CVD (ID 9)
Session Type
Workshop - Metabolism of Lipids and Lipoproteins
Date
Mon, 22.05.2023
Session Time
11:00 - 12:30
Room
Hall: Rudolf Virchow
Presenter
Lecture Time
11:50 - 12:00

Abstract

Background and Aims

Chronic inflammation and immune dysregulation drive atherosclerosis development in rheumatoid arthritis (RA). Recent evidence suggests a link via humoral responses against high-density lipoproteins (HDL). However, their specificity, clinical relevance and emergence along disease course are unknown, especially during the earliest phases of RA.

Methods

IgG and IgM serum levels of antibodies against HDL (anti-HDL) and Apolipoprotein A1 (anti-ApoA1) were measured in 82 early RA patients, 14 arthralgia individuals and 96 controls. Established RA patients (n=42) were included for validation. Atherosclerosis and vascular stiffness were measured by Doppler-ultrasound. Lipoprotein content, particle numbers and size were measured by H-NMR. Cytokines were measured by immunoassays. A cardiometabolic-related protein panel was evaluated using high-throughput targeted proteomics.

Results

Anti-HDL and anti-ApoA1 responses were increased in early RA compared to controls and were comparable to established disease. Only anti-ApoA1 antibodies were increased in arthralgia. IgG anti-HDL and anti-ApoA1 were associated with unfavourable lipoprotein traits in RA and arthralgia, respectively. A similar picture was observed for inflammatory mediators. No associations with clinical features or risk factors were found. IgG anti-HDL were independently associated with atherosclerosis occurrence in early RA, and outperformed patient stratification over conventional algorithms and their anti-ApoA1 counterparts. Anti-HDL antibodies correlated with proteins involved in immune activation, remodelling, and lipid metabolism pathways in early RA.

Conclusions

Humoral responses against HDL particles may be a missing link between inflammation and atherosclerosis along arthritis course, although quantitative and qualitative differences can be noticed. These differences informed distinct capacities as biomarkers and underlying pathogenic circuits.

Hide